Maxcyte (MXCT) Cash & Equivalents (2020 - 2026)

Maxcyte (MXCT) has 7 years of Cash & Equivalents data on file, last reported at $14.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 37.75% year-over-year to $14.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.6 million (down 37.75% YoY) and the FY2025 annual result came in at $20.1 million, down 28.04% from the prior year.
• Cash & Equivalents eased to $14.6 million in Q1 2026 per MXCT's latest filing, from $20.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $239.8 million in Q1 2022 and bottomed at $11.1 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $37.0 million (2024), against an average of $47.2 million.
• Peak annual rise in Cash & Equivalents reached 320.3% in 2023, while the deepest fall reached 84.22% in 2023.
• Tracing MXCT's Cash & Equivalents over 5 years: stood at $11.1 million in 2022, then soared by 320.3% to $46.5 million in 2023, then tumbled by 40.04% to $27.9 million in 2024, then retreated by 28.04% to $20.1 million in 2025, then declined by 27.45% to $14.6 million in 2026.
• Per Business Quant, the three latest MXCT Cash & Equivalents figures stand at $14.6 million (Q1 2026), $20.1 million (Q4 2025), and $13.0 million (Q3 2025).

Peer Comparison